Aimovig a New Drug for Migraines Gets Approval from FDA

May 21, 2018  Source: Ddu 203

Aimovig, a ground-breaking drug to prevent Migraines was approved by the FDA last week. Aimovig will be the only player in the market to treat migraines. The new drug has to be taken once a month through an injection similar to an insulin shot or an EpiPen.

 The Migraine drug works by blocking calcitonin gene-related peptide CGRP, a molecule that helps trigger migraine attacks. The most common side effects of Aimovig are irritation around the injected area and constipation. According to the FDA, the cost for the new drug will be $6,900 a year.

The new drug does not all of migraines, but it helps to reduce the infrequent one to two migraines per month than usual. The disorder involves symptoms like depression, diarrhea or constipation, neck and shoulder stiffness, blurry vision, nausea, and fatigue.  The FDA says that the drug reduces 50% of a migraine as there is no complete end to it but most migraine sufferers say that having even one less migraine would significantly improve their lives.

Preventative drugs like Aimovig and three other drugs are at the last stage of research and FDA approval could drastically improve the lives of migraine sufferers. Dr. Stewart J. Tepper a professor of neurology at Dartmouth College say "these medications have the potential to change the way we treat migraines. For now, they look fantastic".

By editor